- Home
- LBTYA vs EWTX Comparison
LBTYA vs EWTX Comparison
Compare LBTYA & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYA | EWTX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LBTYA | EWTX |
|---|---|---|
| Price | $11.30 | $36.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $13.72 | ★ $39.00 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $12.31 |
| 52 Week High | $13.52 | $40.77 |
Technical Indicators
Market Signals| Indicator | LBTYA | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 56.93 |
| Support Level | $10.54 | $28.73 |
| Resistance Level | $11.53 | $40.36 |
| Average True Range (ATR) | 0.40 | 2.61 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 0.40 | 57.73 |
Price Performance
Historical ComparisonAbout LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.